高糖環境和LCN2治療對尿路病原大腸桿菌之感染與膀胱細胞發炎的影響

柯柏維¹、何承勳^1,2、鄭柏青^3,4、劉詩彬⁵

¹新光吳火獅紀念醫院 外科部 泌尿科；²輔仁大學 醫學系；³臺北醫學大學 醫學系 分子寄生蟲暨熱帶疾病學科；⁴臺北醫學大學 國際熱帶醫學研究中心；⁵國立臺灣大學醫學院附設醫院 泌尿部

The Effect of Hyper-SUGAR Situation and LCN2 Treatment to the Uropathogenic Escherichia Coli Infection and Induced Inflammation in Bladder Cells

Po-Wei Ko¹, Chen-Hsun Ho^1,2, Po-Ching Cheng^3,4, Shih-Ping Liu⁵

Division of Urology¹, Department of Surgery, Shin Kong Wu Ho-Su Memorial Hospital, Taipei, Taiwan;

School of Medicine², Fu Jen Catholic University, New Taipei City, Taiwan;

Department of Molecular Parasitology and Tropical Diseases³, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan;

Center for International Tropical Medicine⁴, School of Medicine, College of Medicine, Taipei Medical University, Taipei, Taiwan;

Department of Urology⁵, National Taiwan University Hospital and College of Medicine, Taipei, Taiwan

Purpose: The study investigated the effects of hyper-sugar situation and the antimicrobial peptide (lipid-carrying protein-2, LCN2) treatment to the UPEC infection in bladder cells, and identified the induced-inflammation and its regulatory pathways.

Materials and Methods: We used in vitro GFP-UPEC infected model in bladder cell line, combining with the blocking JAK/STAT pathway experiments to assess the interaction of LCN2 and glucose influencing the UPEC infection and inflammation in bladder cells.

Results: The present study showed the suppressive effects of LCN2 on UPEC infection and induced inflammation in bladder epithelial cells in a high-glucose environment.

Conclusions: The results will help clarify the correlation between AMP production and UTI, identify the relationship between urinary tract infection and diabetes in UTI patients, and develop novel diagnostics or possible treatments targeting AMP. The results may contribute to the treatment and prognosis study of subsequent urinary tract infections in diabetic patients.